Wedbush Equities Analysts Lift Earnings Estimates for AVTX

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Stock analysts at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a research report issued to clients and investors on Thursday, March 20th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.25) per share for the quarter, up from their prior forecast of ($1.40). Wedbush currently has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics’ Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($0.94) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($1.40) EPS.

Several other equities analysts have also issued reports on AVTX. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Piper Sandler began coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $23.00 price target for the company. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $36.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Trading Up 11.9 %

Shares of Avalo Therapeutics stock opened at $8.54 on Monday. Avalo Therapeutics has a 1 year low of $4.60 and a 1 year high of $34.46. The company has a 50-day moving average of $7.51 and a 200 day moving average of $9.14.

Hedge Funds Weigh In On Avalo Therapeutics

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics in the fourth quarter worth $145,000. Northern Trust Corp bought a new position in shares of Avalo Therapeutics during the fourth quarter worth $168,000. Finally, Bank of Montreal Can purchased a new position in Avalo Therapeutics during the fourth quarter valued at $446,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.